Provided by Tiger Trade Technology Pte. Ltd.

IceCure Medical Ltd.

2.12
-0.0200-0.93%
Volume:29.44K
Turnover:63.12K
Market Cap:7.26M
PE:-0.32
High:2.22
Open:2.18
Low:2.10
Close:2.14
52wk High:42.00
52wk Low:2.06
Shares:3.43M
Float Shares:2.20M
Volume Ratio:0.90
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.6592
EPS(LYR):-7.1047
ROE:-228.31%
ROA:-73.88%
PB:0.61
PE(LYR):-0.30

Loading ...

Icecure Medical Ltd : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $1

THOMSON REUTERS
·
May 04

IceCure Medical announces special shareholder meeting via remote communication

Reuters
·
Apr 23

IceCure Medical Sees 30%+ U.S. ProSense Revenue Jump as SBI 2026 Data Underscore Cryoablation Cost Benefits

TIPRANKS
·
Apr 21

IceCure expects Q1 US ProSense revenue to rise over 30% on year

Reuters
·
Apr 21

IceCure Medical files to sell 16M ordinary share for holders

TIPRANKS
·
Apr 02

IceCure prices $4.0 million registered direct offering at $0.50 per share; adds Series B and C warrants at $0.55 exercise price

Reuters
·
Mar 26

Icecure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

THOMSON REUTERS
·
Mar 26

IceCure Medical files Form 3 initial beneficial ownership statement; director Ron Mayron reports 296,631 ordinary shares

Reuters
·
Mar 26

IceCure Medical; CEO and director Eyal Shamir files initial beneficial ownership statement```

Reuters
·
Mar 26

IceCure Medical Posts Strong 5-Year Kidney Cancer Cryoablation Data From ICESECRET Trial

TIPRANKS
·
Mar 25

IceCure Medical reports results from clinical trial of ProSense for SRMs

TIPRANKS
·
Mar 25

IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm

Reuters
·
Mar 25

Icecure Medical Ltd - 89.4% Recurrence-Free Rate for Tumors ≤3 Cm, 83.9% for General Population at 4 Years

THOMSON REUTERS
·
Mar 25

Icecure Reports Positive 5-Year Top-Line Results From Icesecret Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

THOMSON REUTERS
·
Mar 25

IceCure Medical Names New CFO and Plans Key Leadership Changes Amid ProSense® Growth

TIPRANKS
·
Mar 24

IceCure names Meir Peleg CFO effective May 17, 2026

Reuters
·
Mar 24

BRIEF-Icecure Appoints Meir Peleg As Chief Financial Officer

Reuters
·
Mar 24

Icecure Appoints Meir Peleg as Chief Financial Officer

THOMSON REUTERS
·
Mar 24

Press Release: IceCure Appoints Meir Peleg as Chief Financial Officer

Dow Jones
·
Mar 24

Icecure Medical Rides FDA, ASBRS Wins to Growth

TIPRANKS
·
Mar 18